Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Daniela Tropea

Assistant Professor (Psychiatry)
TRINITY CENTRE, S J H

Assistant Professor (Trinity Inst. of Neurosciences (TCIN))


Details Date
Invited Plenary Speaker for Growth Hormone and IGF conference, Seattle, USA
Invited speaker for the European College NeuropsychiPharmachology Annual meeting 2019, Copenhagen, Denmark
External Reviewer PhD Thesis- University of Sidney June 2015
External Reviewers PhD Thesis-University of Trento 16 October
Invited Speaker for the meeting om Neuropsychiatric Disorders and Synaptic Plasticity, Cardiff, UK, April 2017
INVITED TALKS Trinity College Institute of Neuroscience Annual Meeting (Ireland) November 2013 Irish Rett Syndrome Association (Athlone, Ireland) September 2013 American College Neuropharmachology Annual Meeting (FL, USA) December 2012 Imperial College London (UK) October 2012 Annual Symposium IRSF (VA, USA) June 2011
Mount Sinai School of Medicine (NY, USA) February 2011 Ohio State University (OH, USA) January 2011 Kings College London (UK) December 2010 World Congress Psychiatric Genetics (Athens, Greece) October 2010 Symposium on rare genetic diseases (Viareggio, Italy) February 2010 World Congress Psychiatric Genetics (San Diego, CA) November 2009 European Conference on Rett Syndrome (Milan, Italy) June 2009
Stony Brook University (NY) April 2009 Rutgers University (NJ) December 2008 Stanford University (CA) September 2008 Ecole Normale Superieure (Paris) April 2008 University of Chicago (IL) February 2008 Center for Brain Repair Cambridge (UK) February 2008 University of California Santa Barbara (CA) April 2007 University of Rochester (NY) August 2006
Grant reviewer for Theleton Funding Agency 2009
Invited Associate Editor for Neural Plasticity
Reviewer for the Grant Agency Ontario Mental Health Foundation
Reviewer for the grant Agency Israel Science Foundation
Reviewer for the Funding Agency Wellcome Trust
Reviewer for the Funding Agency MRC
Reviewer for the following peer-reviewed scientific Journals: Neuron, Scientific Reports, Molecular and Cellular Neuroscience, European Journal of Neuroscience, Journal of Neuroscience, Genes, Brain and Behavior, Biological Psychiatry, Neural Plasticity, PlosOne, Frontiers in Cellular Neuroscience, Journal of Neuroscience Research, Experimental Gerontology, NeuroMolecular Medicine and Neuroinformatics.
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
Italian Fluent Fluent Fluent
Details Date From Date To
Associate Member-American College of Neuropshychopharmacology (ACNP) 1 Jan 2016 Present
Society for Neuroscience October 1997 December 2018
Daniela Tropea, IGF1 and derivatives in the treatment of neurodevelopmental disorders, European College of Neuropharmachology annual meeting, September, 2019, ECNP, Notes: [Invited speaker], Invited Talk, PUBLISHED
Sanfeliu, A. and Kaufmann, W.E. and Gill, M. and Guasoni, P. and Tropea, D., Transcriptomic Studies in Mouse Models of Rett Syndrome: A Review, Neuroscience, 413, 2019, p183-205 , Notes: [cited By 0], Journal Article, PUBLISHED  DOI
Sanfeliu, A. and Hokamp, K. and Gill, M. and Tropea, D., Transcriptomic analysis of Mecp2 mutant mice reveals differentially expressed genes and altered mechanisms in both blood and brain, Frontiers in Psychiatry, 10, (278), 2019, Notes: [cited By 1], Journal Article, PUBLISHED  TARA - Full Text  DOI
Daniela Tropea, Role of Insulin-like Growth Factor 1 in the brain, Growth Hormone and IGF conference, Seattle, USA, 14 September , 2018, Notes: [Invited Plenary Speaker], Invited Talk, PRESENTED
S.Shovlin & D. Tropea, Transcriptome level analysis in Rett syndrome using human samples from different tissues, Orphanet Journal of Rare Diseases, 13, (1), 2018, p113 - 128, Journal Article, PUBLISHED  TARA - Full Text  DOI
1. C. Keogh, G. Pini, A. H. Dyer, S. Bigoni, P. DiMarco, I. Gemo,, R. Reilly, D. Tropea, Clinical and Genetic Rett Syndrome Variants are Defined by Stable Electrophysiological Profiles, BMC Pediatrics, 18, (1), 2018, p333 - 348, Journal Article, PUBLISHED  TARA - Full Text  DOI
Tropea, D. and Hardingham, N. and Millar, K. and Fox, K., Mechanisms underlying the role of DISC1 in synaptic plasticity, Journal of Physiology, 596, (14), 2018, p2747-2771 , Notes: [cited By 1], Journal Article, PUBLISHED  TARA - Full Text  DOI
Keogh, C. and Pini, G. and Dyer, A.H. and Bigoni, S. and Dimarco, P. and Gemo, I. and Reilly, R. and Tropea, D., Clinical and genetic Rett syndrome variants are defined by stable electrophysiological profiles 11 Medical and Health Sciences 1109 Neurosciences, BMC Pediatrics, 18, (1), 2018, Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
Daniela Tropea, DISC1 in Activity-dependent plasticity, Neuroplasticity and synaptic function inneuropsychiatric disorders, Cardiff, UK, 27 - 28 April , 2017, Invited Talk, PRESENTED
Daniela Tropea, Understanding the biology of brain disorders with brain plasticity, weekly talks, Carnegie Mellon University, March, 2017, Notes: [Invited Speaker], Invited Talk, PRESENTED
  

Page 1 of 8

  

Award Date
Travel grant for SfN. Boston Area Neuroscience Group (BANG) 2006
Innovative treatment for rare diseases_TIAMO foundation June 2014
Best Project for TTO-organized program 14 March 2014
I study the molecular mechanisms involved in neurodevelopmental disorders with a particular interest in Schizophrenia and Rett Syndrome. I was the first to show that Insulin-like growth factor 1 (IGF1) controls brain plasticity during postnatal development. My first translational work on IGF1 and Rett syndrome stands out for its clinical relevance. Rett syndrome is a severe disorder that lacks a treatment: I showed that IGF1, a growth factor used in children with growth impairments, is able to ameliorate the symptoms of the disease in a mouse model of Rett, and therefore has the potential of leading to a treatment for Rett and other neurodevelopmental disorders (Tropea et al., 2009). Nine clinical trials derived from this study, and I participated to safety clinical trials, which showed no side-effects of IGF1 administration in Rett patients (Pini et al., 2012, Pini et al., 2014, 2016). I have access to exclusive EEG data and blood samples from patients involved in IGF1-related trials. I collaborate with MIT, Neuren Pharmaceuticals, Tuscany Rett Center and Boston Children's Hospital, to study the RNA expression in the blood of Rett patients before and after treatment with IGF1. We aim at identifying, where possible, molecular determinants of IGF1' action in the patients responsive to treatment. I plan to focus my research on the identification of measurable biomarkers and on the effects of IGF1 for the treatment of neurodevelopmental disorders. This research has application in the design and interpretation of current and future clinical trials for assessing the efficacy of IGF1 (current active trails in Rett Syndrome, FragileX, Phelan McDermid and autism). My expertise in growth factors and IGF1 are broadly recognized and I am invited as regular and plenary speaker to international meetings to discuss the topic.